Phase IIa trial of SPI 017 for the treatment of pain associated with spinal stenosis.
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2013
At a glance
- Drugs SPI 017 (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- Sponsors Sucampo Pharmaceuticals
- 07 Aug 2013 This trial is expected to conclude in the fourth quarter of 2013, according to a Sucampo Pharmaceuticals media release.
- 14 May 2013 New trial record